Tag: entrepreneurs
-
Patent Awarded for Focused Ultrasound Skin Treatments
A company developing non-invasive ultrasound treatments for treating skin disorders and removing tattoos received a patent for its technology.
-
Cancer Detection Start-Up Gains $4M in Seed Funds
A developer of early-stage non-invasive cancer detection tests based on research in university labs is raising $4 million in its seed venture round.
-
Gut-Brain Meds Developer Going Public in Merger
31 Oct. 2022. A developer of synthetic biology treatments for inflammatory and neurological disorders linked to the gut is becoming a public company through a special acquisition merger. Intrinsic Medicine Inc. in Seattle is joining with Phoenix Biotech Acquisition Corp. in Oakland, California, a special purpose acquisition company or SPAC, in a deal expected to…
-
Dual-Action Vaccine Shown to Attack, Shrink Solid Tumors
Research with lab animals shows an experimental cancer vaccine generates immune-system cells that infiltrate solid tumors and reduce the tumor’s protective environment.
-
Immunotherapy Start-Up Launches Collaboration, Raises $65M
A new biotechnology company is creating cancer immunotherapies that it says harness more of the full power of T-cells in the immune system to attack tumors.
-
Grant Funds Regenerative Gel for Treating Skin Ulcers
A California state research agency is funding preclinical development of a gel designed to regenerate stem cells in the skin to help heal venous skin ulcers.
-
Infographic – Q3 Digital Health Venture Funds Slide
Venture funding for start-ups worldwide applying digital technologies to health care continued to fall in the third quarter of 2022, both in deals and dollars invested.
-
Trial in Progress of Antibody Blocking Covid-19 in Immunocompromised
A clinical trial is underway testing a synthetic antibody designed to prevent SARS-CoV-2 viral infections in people with compromised immune systems.
-
“Dark Genome” Drug Discoverer Gains $37M in Early Funds
19 Oct. 2022. A biotechnology enterprise discovering new drugs from non-protein coding regions of the genome is raising €37.5 million ($US 36.6 million) in venture funds. Nucleome Therapeutics Ltd. in Oxford, U.K. is a three year-old business spun-off from genetic research labs at University of Oxford medical school. Nucleome Therapeutics is seeking new treatments for…
-
Three Tips for Starting as a Freelance Consultant
What does it take to be an effective freelance consultant?